Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have been given an average rating of “Buy” by the twenty-six brokerages that are currently covering the company, Marketbeat Ratings reports. Four analysts have rated the stock with a sell rating, four have given a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $134.45.
A number of research firms have issued reports on ALNY. Zacks Investment Research raised shares of Alnylam Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday. BidaskClub upgraded Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, March 14th. Piper Jaffray reiterated a “buy” rating and set a $182.00 target price on shares of Alnylam Pharmaceuticals in a research note on Sunday, January 7th. Jefferies Group set a $156.00 target price on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, February 9th. Finally, BMO Capital Markets lowered their target price on Alnylam Pharmaceuticals from $165.00 to $160.00 and set an “outperform” rating on the stock in a research note on Friday, February 9th.
In related news, COO Yvonne Greenstreet sold 7,221 shares of the business’s stock in a transaction dated Monday, March 26th. The stock was sold at an average price of $136.54, for a total value of $985,955.34. Following the sale, the chief operating officer now directly owns 7,221 shares in the company, valued at approximately $985,955.34. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Laurie Keating sold 1,562 shares of the business’s stock in a transaction dated Tuesday, March 20th. The shares were sold at an average price of $149.83, for a total value of $234,034.46. Following the completion of the sale, the senior vice president now owns 16,062 shares in the company, valued at $2,406,569.46. The disclosure for this sale can be found here. Insiders sold a total of 198,620 shares of company stock worth $28,404,143 over the last 90 days. 4.30% of the stock is currently owned by company insiders.
A number of institutional investors have recently made changes to their positions in ALNY. Strs Ohio bought a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at about $141,000. CENTRAL TRUST Co increased its position in shares of Alnylam Pharmaceuticals by 746.3% during the fourth quarter. CENTRAL TRUST Co now owns 1,134 shares of the biopharmaceutical company’s stock valued at $144,000 after buying an additional 1,000 shares during the period. Livforsakringsbolaget Skandia Omsesidigt bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $165,000. American International Group Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $255,000. Finally, Vident Investment Advisory LLC bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $262,000. Institutional investors and hedge funds own 92.00% of the company’s stock.
ALNY traded up $1.97 during mid-day trading on Friday, reaching $98.16. 326,761 shares of the stock were exchanged, compared to its average volume of 990,477. The company has a debt-to-equity ratio of 0.02, a current ratio of 12.23 and a quick ratio of 12.23. The company has a market capitalization of $9,786.75, a price-to-earnings ratio of -18.11 and a beta of 2.68. Alnylam Pharmaceuticals has a 1 year low of $49.19 and a 1 year high of $153.99.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported ($1.48) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.38) by ($0.10). The firm had revenue of $37.90 million for the quarter, compared to analysts’ expectations of $19.31 million. Alnylam Pharmaceuticals had a negative return on equity of 41.08% and a negative net margin of 545.95%. Alnylam Pharmaceuticals’s revenue was up 116.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.32) earnings per share. equities analysts anticipate that Alnylam Pharmaceuticals will post -7.02 EPS for the current year.
WARNING: “Alnylam Pharmaceuticals, Inc. (ALNY) Given Average Rating of “Buy” by Brokerages” was originally published by Macon Daily and is the property of of Macon Daily. If you are reading this report on another website, it was stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be accessed at https://macondaily.com/2018/04/20/alnylam-pharmaceuticals-inc-alny-given-average-rating-of-buy-by-brokerages.html.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.